ANTHONY EVNIN
Profile
First Name
: ANTHONY
Middle Name
:
Last Name
: EVNIN
Related Companies
Titles
Company Name
Related People
DIRECTOR
MICHAEL BAILEY, KEN BATE, KENNETH M. BATE, DOUGLAS COLE, RONALD DEPINHO, ELAN EZICKSON, NICHOLAS GALAKATOS, JENO GYURIS, TUAN HA-NGOC, ROBERT HIGGINS, RUSSELL HIRSCH, DAVID JOHNSON, DAVID JOHNSTON, RAJU KUCHERLAPATI, WILLIAM SLICHENMYER, HENRI A. TERMEER, JOSEPH VITTIGLIO, KENNETH WEG, ROBERT C. YOUNG
DIRECTOR
BRADLEY BOLZON, POL BOUDES, CARL GOLDFISCHER, CARL GOLDFISCHER, M.D., DONALD HILL, DAVID KARPF, HARI KUMAR, PH.D., LOUIS LANGE, LOUIS G. LANGE, M.D., PH.D., CHARLES MCWHERTER, CHARLES A. MCWHERTER, PH. D., EDWARD PENHOET, EDWARD E. PENHOET, PH.D., PAUL QUINLAN, SUJAL SHAH, DAAN VAN DEN NOORT, HAROLD VAN WART, HAROLD VAN WART, PH. D., KURT VON EMSTER, ROBERT J. WILLS, ROBERT ZERBE
DIRECTOR
PETER COUROSSI, STEVEN ERTEL, ANTHONY B EVNIN, PAT GAGE, JEAN GEORGE, GEORGE GOLUMBESKI, CARL GORDON, CARL L. GORDON, ED KANIA, EDWIN M. KANIA, EDWIN M. KANIA, JR., JOHN KNOPF, TOM MANIATIS, TERRANCE G. MCGUIRE, TERRY MCGUIRE, KEVIN F. MCLAUGHLIN, RICHARD POPS, RICHARD F. POPS, JASBIR SEEHRA, MATTHEW L. SHERMAN, ROBERT STEININGER, WYLIE VALE, WYLIE W. VALE, JOSEPH S. ZAKRZEWSKI
DIRECTOR
DIRECTOR
JAMES E. AUDIA, GAREN BOHLIN, SCOTT BRAUNSTEIN, MICHAEL R. COOPER, KEITH DIONNE, DAVID GOEDDEL, MARK A. GOLDSMITH, EDWARD E. HARLOW, JR., STEVEN HOERTER, MATTHIAS JAFFE, MARK LEVIN, TOM MANIATIS, STEVEN PAUL, JIGAR RAYTHATHA, EMMA REEVE, KERRY K. REINERTSEN, ADRIAN SENDEROWICZ, PETER SVENNILSON, ROBERT TEPPER, ELIZABETH G. TREHU, PATRICK TROJER, KAREN VALENTINE
DIRECTOR
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2019-10-01
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
$25,000,001 - $100,000,000
Equity
2017-09-26
D/A
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
$5,000,001 - $25,000,000
Equity
2015-06-29
D/A
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
$5,000,001 - $25,000,000
Equity
2015-06-29
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
NO REVENUES
Equity
2015-06-29
D
PHARMACEUTICALS
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2011-05-31
D
PHARMACEUTICALS
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2010-11-03
